NIKKEI 225
38,614.90 -18.12 (-0.05%) HANG SENG
18,060.86 -274.46 (-1.50%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,378.70 +9.70 (+0.41%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
51,031.94 -688.19 (-1.33%)
BDTX Sep 2024 10.000 call
| Previous close | 0.8500 |
| Open | 0.6000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 10.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.6000 - 0.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireBlack Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial demonstrated BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology
- GlobeNewswire
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 4-6, 2024, in New York, NY. Presentation details are as follows: 7:30-7:55am ET on Wednes
Simply Wall St.Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the company
Key Insights Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to...
